Emergent BioSolutions' ACAM2000®, ( Smallpox and Mpox ( Vaccinia ) Vaccine, Live ) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
GAITHERSBURG, Md., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental Biologics License Application ( sBLA ) for the expansion of the indication for ACAM2000®, ( Smallpox and ...
| Ticker |
Sentiment |
Impact |
|
SPOT
|
Neutral
|
3 %
|
|
EBS
|
Neutral
|
6 %
|
